Breast Cancer CDK 4/6 Inhibition

  • Skill Levelintermediate
  • Enrolled 1,207 students enrolled
Enquire now

Key concepts covered include:

By the end of this module, you should be able to:

  • Focus on CDK4 and 6 as key regulators of the G1- S transition of the cell cycle.
  • Acknowledge that an array of substrates for CDK4 and 6 have been identified, including the retinoblastoma protein, RB1, which can potentially lead to drug target discovery.
  • Describe the mechanisms and clinical implications of endocrine resistance.
  • Define an evidence-based algorithm for the management of hormone-positive breast cancer progressing on endocrine therapy.
  • Define a differential algorithm for primary and secondary endocrine-resistant breast carcinoma.
  • Establish a paradigmatic sequential path of clinical utility to drive therapeutic decision-making of your working group.
  • Illustrate the hypothetical role of CDK4/6 inhibitors in the neoadjuvant and adjuvant settings of care.
  • Assess adequately and treat early the preventable adverse events of CDK4/6 inhibitors with a special focus on neutropenia.
  • Explain the clinical benefit of CDK 4/6 inhibitors.
  • Learn how to manage the side effects of CDK4/6 inhibitors.
  • Be aware of adverse events and challenges.
  • Share your knowledge with your oncology team and your patients.

What you'll learn

This course is a collection of modules on breast cancer CDK 4/6 inhibition, developed to support the professional development of three distinct healthcare professions.

Instructor

ecancer

ecancer – Oncology


4/5

ecancer’s mission is to raise the standards of care for cancer patients across the world through education.

Course Preview

Instructor

ecancer

ecancer – Oncology


4/5

ecancer’s mission is to raise the standards of care for cancer patients across the world through education.

For: intermediates
Last Updated 07/2021

Other Top Rated Courses by ecancer

Our alumni and partners

This will close in 0 seconds

X
or
or

Have an account?